Table 2.
Duration of follow-up and distribution of patients with complete and censored lines of therapy by SMKI regimen
| Measure | First LOT Regimen | p valuea | ||||||
|---|---|---|---|---|---|---|---|---|
| Total (N = 217) | Sorafenib (n = 80) | Sunitinib (n = 29) | Lenvatinib (n = 29) | Vandetanib (n = 28) | Pazopanib (n = 24) | Other (n = 27) | ||
| Duration of follow-up, months | ||||||||
| Mean (SD) | 499.0 (413.5) | 472.8 (388.5) | 631.0 (453.4) | 249.3 (127.0) | 685.8 (526.5) | 387.8 (441.5) | 608.2 (332.1) | < 0.001 |
| Median | 378.0 | 371.5 | 596.0 | 259.0 | 473.5 | 219.5 | 570.0 | |
| Complete LOT, n (%) | 155 (71.4) | 64 (80.0) | 23 (79.3) | 10 (34.5) | 21 (75.0) | 16 (66.7) | 21 (77.8) | < 0.001 |
| Complete LOT end criteria, n (%)b | ||||||||
| Death | 11 (7.1) | 4 (6.3) | 4 (17.4) | 0 | 0 | 2 (12.5) | 1 (4.8) | 0.242 |
| Start of new agent | 16 (10.3) | 5 (7.8) | 3 (13.0) | 1 (10.0) | 4 (19.1) | 2 (12.5) | 1 (4.8) | 0.621 |
| ≥ 60 day treatment gap | 128 (82.6) | 55 (85.9) | 16 (70.0) | 9 (90.0) | 17 (81.0) | 12 (75.0) | 19 (90.5) | 0.413 |
| Censored LOT, n (%) | 62 (28.6) | 16 (20.0) | 6 (20.7) | 19 (65.5) | 7 (25.0) | 8 (33.3) | 6 (22.2) | < 0.001 |
| Censoring criteria, n (%)b | ||||||||
| End of study | 22 (35.5) | 1 (6.3) | 2 (33.3) | 13 (68.4) | 2 (28.6) | 0 | 4 (66.7) | |
| End of continuous enrollment | 40 (64.5) | 15 (93.8) | 4 (66.7) | 6 (31.6) | 5 (71.4) | 8 (100.0) | 2 (33.3) | |
| Measure | Second LOT Regimen | p valuea | ||||||
|---|---|---|---|---|---|---|---|---|
| Total (N = 77) | Sorafenib (n = 19) | Sunitinib (n = 15) | Lenvatinib (n = 10) | Cabozantinib (n = 8) | Vandetanib (n = 7) | Other (n = 18) | ||
| Complete LOT, n (%) | 51 (66.2) | 13 (68.4) | 12 (80.0) | 3 (30.0) | 5 (62.5) | 6 (85.7) | 12 (66.7) | 0.163 |
| Complete LOT end criteria, n (%)b | ||||||||
| Death | 1 (2.0) | 1 (7.7) | 0 | 0 | 0 | 0 | 0 | 1.000 |
| Start of new agent | 3 (5.9) | 0 | 1 (8.3) | 0 | 1 (20.0) | 0 | 1 (8.3) | 0.455 |
| ≥ 60 day treatment gap | 47 (92.1) | 12 (92.3) | 11 (91.7) | 3 (100.0) | 4 (80.0) | 6 (100.0) | 11 (91.7) | 0.828 |
| Censored LOT, n (%) | 26 (33.8) | 6 (31.6) | 3 (20.0) | 7 (70.0) | 3 (37.5) | 1 (14.3) | 6 (33.3) | 0.163 |
| Censoring criteria, n (%)b | ||||||||
| End of study | 9 (34.6) | 2 (33.3) | 0 | 5 (71.4) | 0 | 1 (100.0) | 1 (3.9) | |
| End of continuous enrollment | 17 (65.4) | 4 (66.7) | 3 (100.0) | 2 (28.6) | 3 (100.0) | 0 | 5 (83.3) | |
| Measure | Third LOT Regimen | p valuea | ||||||
|---|---|---|---|---|---|---|---|---|
| Total (N = 39) | Pazopanib (n = 7) | Sunitinib (n = 7) | Sorafenib (n = 6) | Vandetanib (n = 6) | Lenvatinib (n = 4) | Other (n = 9) | ||
| Complete LOT, n (%) | 27 (69.2) | 5 (71.4) | 6 (85.7) | 4 (66.7) | 3 (50.0) | 1 (25.0) | 8 (88.9) | 0.228 |
| Complete LOT end criteria, n (%)b | ||||||||
| Death | 2 (7.4) | 0 | 1 (16.7) | 0 | 0 | 0 | 1 (12.5) | 1.000 |
| Start of new agent | 1 (3.7) | 0 | 0 | 0 | 0 | 0 | 1 (12.5) | 1.000 |
| ≥ 60 day treatment gap | 24 (88.9) | 5 (100.0) | 5 (83.3) | 4 (100.0) | 3 (100.0) | 1 (100.0) | 6 (75.0) | 0.852 |
| Censored LOT, n (%) | 12 (30.8) | 2 (28.6) | 1 (14.9) | 2 (33.3) | 3 (50.0) | 3 (75.0) | 1 (11.1) | 0.228 |
| Censoring criteria, n (%)b | ||||||||
| End of study | 7 (58.3) | 1 (50.0) | 0 | 1 (50.0) | 0 | 3 (100.0) | 0 | |
| End of continuous enrollment | 5 (41.7) | 1 (50.0) | 1 (100.0) | 1 (50.0) | 3 (100.0) | 0 | 1 (100.0) | |
All patients had ≥ 1 month follow-up (n = 217)
LOT line of therapy, SD standard deviation
aBy ANOVA for continuous variables and Chi square test for percentages
bPercentages may not sum to 100% due to rounding